Kalevi J. Pulkkanen

TL;DR: It is shown that a soluble form of VEGFR-3 is a potent inhibitor of Vascular endothelial growth factor (VEGF)-C and VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal.

TL;DR: Evaluating the usefulness of various treatment approaches and current clinical status of gene therapy for malignant glioma finds that efficient gene delivery into the brain still presents a major problem, and there is a lack of definitive phase III trials.

TL;DR: It is concluded that caution must be exercised when examining apoptosis in mouse tissues with TUNEL assay, as an intense false-positive apoptotic signal was detected in nude and Balb/c mice kidney and liver.

TL;DR: It is concluded that the inhibition of angiogenesis using ES gene transfer together with the cytotoxic HSV-tk gene therapy results in a significantly improved treatment effect in RCC compared to the single gene treatments.

TL;DR: Adeno-HSV-tk gene therapy may be useful for the treatment of renal cell carcinoma in vivo using herpes simplex virus thymidine kinase (HSv-tk) gene therapy.